Lycia Therapeutics, Inc.

US$30.50As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:LYCAHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR —
Div yield —
ROE —
Biotechnology
Beta (5Y) —
PE TTM —
TSR TTM —
Mkt cap US$1.759B
ROIC —
SE Grade™
Value
Quality
Moat
Consensus
Reference
$29
(4.65%)
(34.02%)
Hold 7|9|1|11|3
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.71
0.70
0.70
0.75
17.19%
19.24%
10.78%
15.44%
Revenue$M
96.73
96.68
98.24
102.6
4.01%
2.60%
(1.47%)
4.32%
Peers (US$1.759B)
Cap (US$)
PE
1.779B
—
1.745B
—
Capital
TTM
5Y
10Y
Leveragex
0.187
0.301
0.224
EBIT/Intx
4.216
1.099
1.048
Own earn%
(5.55)
(34.58)
(34.52)
Sh yield%
37.41
22.75
22.39
Owners
Insiders/Inst%
3.90
72.07
Short interest%
3.57
SBC / revenue%
5.47
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
8
Op margin range%
16–28
$1 testx
0.0
Incr. ROIC%
35